Current Report Filing (8-k)
05 August 2017 - 6:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 3, 2017
Proteostasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-37695
|
|
20-8436652
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
200 Technology Square, 4th Floor
Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(617) 225-0096
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07.
|
Submission of Matters to a Vote of Security Holders
|
Our annual meeting of shareholders
(the Meeting) was held on August 3, 2017. A quorum was present. At the Meeting, our shareholders elected Meenu Chhabra and Jeffery W. Kelly, Ph.D., to serve as Class II directors to serve on our board of directors until the
annual meeting of shareholders to be held in 2020. Prior to the meeting, Helen Boudreau withdrew from consideration for election to the Companys Board following her decision to accept employment as the Companys Chief Financial Officer
and subsequent resignation from the Board. The tabulation of votes with respect to the election of such directors was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
|
Withheld
|
|
|
Broker Non Vote
|
|
Meenu Chhabra
|
|
|
20,382,001
|
|
|
|
824,386
|
|
|
|
2,012,819
|
|
Jeffery W. Kelly, Ph.D.
|
|
|
20,146,510
|
|
|
|
1,059,877
|
|
|
|
2,012,819
|
|
In addition, our shareholders ratified the appointment of PricewaterhouseCoopers LLP as our independent
registered public accounting firm for the fiscal year ending December 31, 2017. The tabulation of votes with respect to these proposals was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
|
Against
|
|
|
Abstain
|
|
Ratification of our Independent Registered Public Accounting Firm
|
|
|
23,153,057
|
|
|
|
7,737
|
|
|
|
58,412
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: August 4, 2017
|
|
|
|
PROTEOSTASIS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jeffrey M. Held
|
|
|
|
|
|
|
Jeffrey M. Held
|
|
|
|
|
|
|
General Counsel and Secretary
|
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2024 to May 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Proteostasis Therapeutics Inc (NASDAQ): 0 recent articles
More Proteostasis Therapeutics, Inc. News Articles